Full-Time

Senior Director

Corporate Controller

Posted on 9/11/2025

ArsenalBio

ArsenalBio

51-200 employees

Programmable cell therapies for solid tumors

Compensation Overview

$280k - $300k/yr

San Bruno, CA, USA

Hybrid

Category
Accounting (1)
Requirements
  • Bachelor’s and/or Master’s Degree in Business Administration with an emphasis in accounting
  • C.P.A. is preferred
  • 15+ years experience in general accounting, financial statement preparation and stock compensation accounting
  • Prior experience as Controller in private and public companies, must have experience in biotech/pharma industry
  • Relevant financial leadership experience, including the building and leading of teams in a fast paced, start up environment
  • Experience filing an S-1
  • Big Four or national accounting firm audit experience is preferred, but not required
  • Strong experience in both the private and public accounting sectors is preferred, but not required
  • Excellent written and verbal communication skills
  • Credibility, ethical, full disclosure and a clean financial history
  • Confidential, understands the ethical standards of a CPA
  • Excellent GAAP and financial reporting technical skills
  • Exceptional work ethic
Responsibilities
  • Responsible for accounting and financial reporting
  • Ensure robust accounting records, and implement appropriate accounting policies and procedures
  • Oversee and manage external vendor responsible for processing payroll, handling accounts payable and other accounting support
  • Generate monthly reporting package: general ledger; proper cutoff; journal entries; account reconciliations
  • Support and oversee implementation of the company’s financial IT systems (ERP, purchase order, bill payment and other ancillary systems)
  • Monitor cash and investments, including compliance with the Company’s cash management policy and treasury internal controls
  • Manage tax returns and tax provision with external tax advisor; R&D tax credit; other annual tasks include 1099's, property tax filings, sales and use tax, CA SOS filing, state annual filings, US Census reports, etc.
  • Treasury/cash management - monitor bank funds to ensure accounts have adequate cash to support needs; approve wire transfers; reconcile bank accounts, provide cash activity summary to management; all journal entries surrounding cash/investments
  • Manage stock administration vendor and annual stock compensation calculations
  • Review monthly accounting close process, including analytical review of the monthly operating results to ensure accurate accounting records are maintained
  • Preparation of monthly financial statements
  • Accurate and timely production of all financial information
  • Proper analytical review of the asset operations from a balance sheet and cash flow perspective as well as an overall business perspective
  • Lead and manage an accounting team

ArsenalBio focuses on developing programmable cell therapies to treat solid tumors. Its core work is in the research, development, and clinical testing of therapies that reprogram cells to recognize and attack solid cancers. The product works by engineering cells (likely immune cells or other therapeutic cells) so they can specifically target solid tumor cells and perform its cancer-fighting function once delivered to patients. The company differentiates itself through its emphasis on programmable cell therapies tailored for solid tumors, its clinical-stage status, diverse and cross-disciplinary team, and its end-to-end focus on translating research into commercially available treatments. ArsenalBio’s goal is to bring these therapies to market and generate revenue by delivering approved treatments to healthcare providers to treat patients with solid tumor cancers.

Company Size

51-200

Company Stage

Series C

Total Funding

$630M

Headquarters

San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • $325M oversubscribed Series C closed September 4, 2024, funds clinical programs.
  • Nate Hardy joined as CFO October 7, 2024, bolstering financial leadership.
  • AB-2100 dosed first patient in Phase 1/2 ccRCC trial using CITE technology.

What critics are saying

  • Bristol Myers Squibb licenses co-developed T-cell programs, sidelining ArsenalBio pipeline.
  • AB-1015 Phase 1 fails efficacy in ovarian cancer from T-cell exhaustion.
  • Cash from $325M Series C burns out post-2026 without Series D funding.

What makes ArsenalBio unique

  • ArsenalBio engineers logic-gated CAR T-cells with dual sensors activating only at tumors.
  • CITE technology integrates transgenes via CRISPR for solid tumor selectivity.
  • Synthetic biology toolkit reprograms T-cells to remodel suppressive microenvironments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision coverage

Virtual & telehealth options

Parental leave

Flexible work schedule

Flexible PTO

Mental health resources

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

5%

2 year growth

5%
Arsenal Biosciences
Jan 6th, 2025
ArsenalBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

South San Francisco, Calif. - January 6, 2025 - Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Ken Drazan, M.D., ArsenalBio's CEO and Chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 4 p.m. PST.

Bakersfield.com
Sep 16th, 2024
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial Officer

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced that Nate Hardy will join its management team as Chief Financial Officer, effective October 7, 2024.

William Reed Business Media
Sep 5th, 2024
ArsenalBio bags $325 million to develop CRISPR-engineered cell therapies

ArsenalBio bags $325 million to develop crispr-engineered cell therapies.

Arsenal Biosciences
Sep 4th, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs through Clinical Development • Arsenal Bio

Oversubscribed Series C welcomes multiple new investors South San Francisco, Calif. – September 4, 2024 – Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the close of an oversubscribed $325 million Series C financing round. The funding round included new […]

CityBiz
Sep 4th, 2024
T. Rowe Price Joins $325 Million Financing for ArsenalBio

T. Rowe Price joins $325 million financing for ArsenalBio.

INACTIVE